Member Info for Dustbin101

Yep, you can’t stop them crying.

Yes, as Zenakine sales take off ( all the pointers says it has done already ), and it’s becomes public through the accounts, this share will perform like no other

Just look at the broker note FIG 19 , adoption rates over the next 14 years, and compress them down to 3 or 4

Nothing is in the path of rapid take up by a very large section of the worlds population

***Without Croda's blockbuster then SBTX falls away**

No :the two businesses purchased last year cover all group overheads

That leaves one huge money printing machine to spit out cash at 100% profit

Plus Superdrug, that may go international

Today 09:17

Blockbuster my ar$e, nobody can buy a single product with the Zenakine ingredient anywhere. Will it be available to the general public in time for Xmas, I'm sure bin man can tell us as Ashman's mouthpiece. If not, then a big opportunity missed.

You can buy these so called blockbuster shares for just over 14p, almost 3p less than the big 5 mates bought at the last placing and Ashman and his supporters think he is doing a good job. The bloke is a joke, overpaid, overrated, clueless and useless. Time to go Ashman.

////////////////

Bazz:

Your confused

Croda is in control of Zenakine, it is Croda who will deliver the blockbuster

Toyin

Unlike yourself I have never questioned how successful SBTX will become, or actions taken by the directors.

Never taken issue with a director in my life , I know the score , on the day of purchase, of any company shares.

I know Zenakine will be a blockbuster , always have , you call it a dream .!!

Ashman will see his £1.00 option targets hit

Last week another lump of evidence showed up.

Have no fear :

Zenakine is looking more and more like a blockbuster each day.

Last weeks Croda update was a big shock to the upside, with a step change over the last 3 months, in sales of Croda Actives, AND the fact that that growth has JUST started coming through.

Note for Bazz

PS:

This has nothing to do with Ashman

Some here like to focus on the past, missing the point, that share investment is ALWAYS about future prospect's and profits

Bazz and Toyin are both experts of the past when it comes to SBTX

They delight in wallowing in it , just this morning, they both hit the jackpot .!!

Rather like the sad bastard that sits at the bar every night , bitter and twisted that the Mrs left 30 years ago and took the pet dog with her.

They can not move on

Toyin, cash on the books is not such a bad idea for various reasons.

Safety comes to mind.

Plus can buy the next company quickly, that we all know would please you and Bazz no end .!! ( lol )

SBTX has been de - risked , (yet again), over the last two weeks .

How .?

1/ Sales in Superdrug have gone live, producing yet another income stream.

2/ Conformation from Croda that New and Protected Active sales, are rocking.

Zenakine in the number one , New and Protected, Active Croda has ; ( by addressable market ).

Toyin

Have no fear.

Actives growth is starting to come through. ( you say that, when you have long term orders, and know future production, and sales call offs ).

Active sales have already been up each Q this year

That growth does not even acknowledge sales of Zenakine may have replaced those of Matrixyl

Matrixyl has zero growth in Croda Q3

One might safely assume, Matrixyl sales fell, as Croda clients ran down stocks in preparation for the change to Zenakine.

No ramping from me, based on real numbers and real comments from the Croda CEO last week.

Nice to see some independent research .

Well done

My take

Annual Royalty Income for :SBTX FY ending June 2026

£1.05M @ 10% from Croda.

This implies Croda itself sells £10.5M of Zenakine in the SBTX full year, (adjusted for payment after a 3 month delay.)

First of all , i 100% agree this could be the kind of numbers the broker puts out.

Where I differ is on the amount of royalty income, for the year.

Last week Croda reported a 12% jump in its Q3 actives sales numbers V the same period last year.

The CEO also said all the growth was from new products

He also informed Croda shareholders that Actives had been on the up in Q1, Q2, with a step change in Q3

He also said Actives growth was STARTING TO COME THROUGH ( Zenakine is an active ).

Matrixyl sales fell or were flat, since they are not new

We do not know how much Matrixyl was replaced with Zenakine (if any).

We do know skincare is 70% of Croda sales within beauty

We also know Zenakine has been pushed by Croda since launch.

Croda does have other new Actives, so one needs to perhaps half the growth rate, within Actives, to reflect Zenakine is not responsible for all the sales growth.

After all that, I arrive at at least £6.5M of Croda Zenakine sales in the first 3 months of the SBTX year or £650,000

Add on some Zenakine sales growth over the next 3Q and this year we could be looking at some very, very, serious profits

Clearly 2026 at

RE: Royalties

Dustbin, the SInger note does include Croda royalty revenues "We assume an uplift in FY26E gross profit margin to 63.9%, reflecting an improved sales mix, and Croda royalties which drop through to the bottom line, with gross profit therefore expected to be £4.0m.We assume a further uplift in FY27E gross profit margin to 69.8%, with gross profit therefore expected to be £5.7m reflecting an improving revenue mix from higher margin Croda royalties"

///////////////////////////////////////////////

Those royalties do not show on the chart within the broker note :

Singer broker forecasts ; 17th July 2025 : Page 19 ( fig 18), scenarios highlighting Croda royalty in UK pounds ( Millions )

These are presented in a chart format.

For the SBTX year ending June 30 2025

No Croda revenue

For the SBTX year ending June 30 2026

No Croda revenue

/////////////////////////////////////////////////////////////////////////////////////////////////////////////::::

So the chart does not reflect the broker forecasts ;

Thus the broker has increased the gross margin for year ending 2026 from 2025 to include Croda income of £240,000 ( 6 ticks on higher revenue ).

That might be the reason it is not showing on his chart .

/////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////

This implies Croda revenues produced in SBTX Q1 to be paid to SBTX 3 months later of £240,000 divided by 4 quarters = £60,000

That number would require Zenakine sales of £600,000 in their Q3 just reported .

Since Croda Actives jumped by 12% in Q3 v Q3 last year, and Actives have seen growth in Croda Q1,Q2, and Q3 of this year we know for a fact the broker upgrade is coming.

Toyin

I see you like to tell SBTX how to run their business as well ..!!!!

Toyin

2 days ago

email reply I have sent to Axis, regarding NPF & gummies/gum. I’m sure it will be completely ignored as I am just a pleb.

Hi Holly

Thank you for the reply.

So we can use the word psoriasis on the Superdrug website, we can use the word psoriasis on our own website, but you cant say NPF accreditation or use the logo along with National Psoriasis Foundation anywhere because it says psoriasis? That sounds a little crazy to say the least.

I wouldn't expect anyone to swallow the gum, I understand it will be delivered by the saliva. Regarding the gummy, I'm not suggesting the gummy would be an amount of food that would effect the probiotic. What I am saying is the Bright study instructions were crystal clear and the results were based on the instructions being followed. I know Prof Cath was very clear that consistency and empty stomach were key.

The chances of customers buying gummies/chewing gum and taking them on empty stomachs is basically zero, you aren’t going to throw a dozen gummies down your neck one hour before breakfast or two hours after dinner, same with the chewing gum, you will snack on them during the day, ergo, not on an empty stomach, then you will most likely get efficacy issues and consumers will stop buying because it doesnt work.

I think it is a very bad idea to go down this route, capsules, completely understand, gummies/gum, non starter.

I would also suggest putting this on the Superdrug website as you have on our website.

"We recommend taking AxisBiotix for at least 2 months to allow sufficient time for visible results. Since everyone's skin is unique, the timeline for experiencing changes may vary.”

I would also suggest an introductory offer of two for one.

Kind regards

Chris

Toyin

We have had enough of your drivel , shares are about future earnings growth .

The broker will not have access to any more information on Croda revenues than you or me.

You have a brain , use it , like I have , picking up on this weeks Croda 3Q sales

CRODA.



Beauty actives sales are difficult to track within Croda accounts on a sequential basis

The published numbers are of little use, when attempting to track potential Zenakine sales, as they compare the numbers for the period in question over the same time period , in the previous year.

However through researching a combination of croda accounts and broker presentations over the last year, I have discovered the following to points of reference.

The recent low point for beauty Actives sales was Q4 2024.

From Q1 results 2025

Year-on-year sales were down slightly in Beauty Actives against a good comparator period but were up strongly on a sequential basis compared with the final quarter of 2024.

—————————————————————-/——————————————————————————————————-///

From the Q3 conference call on Thursday, a broker is asking why the sudden jump in Active sales in Q3. ?

ANSWER:

We are we have been growing, by the way, over the last few quarters, but this is a bigger growth, and we're very pleased with that.

Well balanced across local and regional, and multinationals. Actually, it's USA-led and there's many behind the growth figures.

It's not one or two customer wins. It's many product launches with customers of all different shapes and sizes.

Primarily, virtually all of it is on innovation, some great new products coming out and some existing products with new data. So we feel very confident about the Actives business.

````````````````````````````````````````````````````````````````

Q1, Q2, Q3, in 2025 , have seen Actives growth, with a step change in Q3

This I believe , is being led by a large extent by sales of Zenakine, particularly in Q3 , as shipments go out of the door, to be made into client finished products.

What I am so excited about, is another line from the CEO this week contained within the broker call ;

👀You've got a positive mix starting to come through, particularly with actives growing in consumer.👀

** STARTING TO COME THROUGH **

** We feel very confident about the Actives business **

If 12% Actives growth is *starting * to come through you can bet your bottom dollar a great deal more is to come.

A large part of that growth, will come from a mixture of new clients moving over to Zenakine and repeat orders from those clients ,who now have products about to hit the shops that will then need to be replenished.

This is a very , very, powerful mix , and that’s before a good portion of the worlds population gets hooked on its sleep, the feel good factor, and anti ageing qualities.

Toyin :

I am not going to entertain your old rubbish , over and over again.

The subject was Zenakine revenues from Croda over the last 3 months. ( covered by an NDA )

No one can get away from the fact Croda Actives growth was more than excellent and a good lump of it will be down to Zenakine.

Those revenues get reported in SBTX accounts 3 months after Croda itself reports revenues.

//////////////////////////////////////////////////////////////////////////////////////////////////////////////////////

Singer broker forecasts ; 17th July 2025 : Page 19 ( fig 18), scenarios highlighting Croda royalty in UK pounds ( Millions )

These are presented in a chart format.

For the SBTX year ending June 30 2025

No Croda revenue

For the SBTX year ending June 30 2026

No Croda revenue

///////////////////////////////////////////////////////////////////////////////////////////////////////////////////////

Just for once , cerebrate Croda revenues are rocking in , just as predicted. !!

The house broker will at some stage upgrade his SBTX forecast's .

‘’Aquae, yes, the Croda royalty/def con is a mystery. It is a pity we don’t have any transparency, how can we value our investment accordingly. Is that information material? Who knows with this outfit anymore! ‘’

````````````````````````````````````````

Toyin :

Transparency arrives with each set of SBTX results.

Last week another part of the jigsaw was released to Croda investors.

New beauty Actives are driving real growth within that company, (bar cost cutting, and poor quality volume growth, at low margins).

So you have your transparency issue put to bed, from your companies partner, (Croda), who are the ones producing, and delivering , Zenakine to the market.

If you assumed just half of the Croda Actives growth, is from Zenakine then you have some very serious revenues due to SBTX this year 2025 - 2026.

However it’s even more interesting , because in my view , Zenakine has also just begun eating into Matrixyl market share.

So we have extra hidden growth in Zenakine sales, that do not show, within Croda Actives growth. Croda is slowly replacing one old Active, (Matrixyl), with a new Active, (Zenakine).

This is going to produce fantastic returns for SBTX shareholders over the coming years.

I agree with the previous poster, SBTX is at break even or better, across the group, (without any Croda revenues).

SBTX is also loaded with cash.

Finally why is the Croda’s CEO **very confident about his Actives division ** ?

I will tell you, he knows that Zenakine is a blockbuster in the making, having won orders from across the board (multi nationals, and local and regional ).

He also knows that those orders will be on a repeat basis for years to come.

Those SBTX investors that never stop fretting, received a fabulous Croda update this week.

They could not have asked for more, for it points to Zenakine sales racing past the SBTX brokers forecasts.

The Croda Actives growth numbers are real and not produced by Ashman.

Croda results and conference call was loaded with new information this week.

All of it was excellent for those invested here

Point to SBTX earning royalty income of £1M in the first 3 months of our financial year.

This number could be higher

To be paid 3 months in arrears as per the agreement terms.

Based on Zenakine sales of £10M over the period and 10% being due to SBTX

Assuming zero growth of Zenakine sales over the following nine months by Croda , profits due to SBTX will be £4M of which £3M will arrive in the 2025 - 2026 SBTX accounts’ plus the Zenakine income from April - June 2025. ( from the previous year ).

Https://www.croda.com/en-gb/investors/results-presentations-and-reports

It’s not a ban disco, it’s just not going to be viable going forward.

Retinol is being banned above strength bands in the EU.